At a glance
- Originator Astellas Pharma
- Class Antiarrhythmics; Bradycardic agents
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arrhythmias
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Arrhythmias in Japan
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 23 Sep 2002 Preclinical trials in Arrhythmias in Japan (unspecified route)